Harrow, Inc. (NASDAQ:HROW – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $69.4286.
Several research analysts have recently commented on HROW shares. Wall Street Zen lowered Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Zacks Research upgraded Harrow from a “strong sell” rating to a “hold” rating in a research report on Friday, April 3rd. Nomura lowered Harrow to a “neutral” rating in a research report on Wednesday, March 18th. Cantor Fitzgerald decreased their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Finally, B. Riley Financial restated a “buy” rating and set a $65.00 price objective (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th.
Get Our Latest Research Report on Harrow
Harrow Price Performance
Harrow (NASDAQ:HROW – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The firm had revenue of $44.20 million during the quarter, compared to analyst estimates of $52.43 million. Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.During the same quarter in the previous year, the business posted ($0.38) EPS. As a group, analysts forecast that Harrow will post 0.29 EPS for the current year.
Insider Buying and Selling
In related news, CFO Andrew R. Boll acquired 3,500 shares of Harrow stock in a transaction that occurred on Thursday, May 14th. The stock was acquired at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the transaction, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at $24,358,902.10. This trade represents a 0.43% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Adrienne L. Graves acquired 1,000 shares of Harrow stock in a transaction that occurred on Monday, May 18th. The shares were bought at an average price of $31.07 per share, with a total value of $31,070.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at approximately $31,070. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 12.80% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HROW. Royal Bank of Canada boosted its position in Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after purchasing an additional 4,967 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock valued at $483,000 after purchasing an additional 790 shares during the period. Strs Ohio acquired a new position in Harrow during the 1st quarter valued at approximately $149,000. Legal & General Group Plc boosted its position in Harrow by 12.4% during the 2nd quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock valued at $939,000 after purchasing an additional 3,384 shares during the period. Finally, Rhumbline Advisers boosted its position in Harrow by 9.3% during the 2nd quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock valued at $1,434,000 after purchasing an additional 3,994 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.
Harrow Company Profile
Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.
Read More
- Five stocks we like better than Harrow
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
